drugset
drugset / Trial / NCT07011654

Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)

NCT07011654 ↗

Phase 1/2 Recruiting 31 enrolled M.D. Anderson Cancer Center Y-mAbs Therapeutics · collab
NaSingle-groupOpen-labelTreatment

Summary

This phase I/II trial tests the safety, best dose, and effectiveness of naxitamab in combination with sacituzumab govitecan in treating patients with triple-negative breast cancer (TNBC) that has spread from where it first started (primary site) to other places in the body (metastatic).

Timeline

Start
2025-09-19
Primary completion
2028-07-01
Completion
2030-07-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Naxitamab Monoclonal antibody — Intravenous
Subject Sacituzumab Govitecan Monoclonal antibody — Intravenous

Indications

triple-negative breast carcinoma